Business Description
AC Immune SA
ISIN : CH0329023102
Total Employee Number:
122Description
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 17.38 | |||||
Equity-to-Asset | 0.23 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.07 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -5.11 | |||||
Beneish M-Score | -1.91 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -4.1 | |||||
3-Year EBITDA Growth Rate | 1.2 | |||||
3-Year EPS without NRI Growth Rate | 1.2 | |||||
3-Year FCF Growth Rate | 3.1 | |||||
3-Year Book Growth Rate | -36.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 245.15 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.41 | |||||
9-Day RSI | 53.41 | |||||
14-Day RSI | 51.39 | |||||
3-1 Month Momentum % | -12.68 | |||||
6-1 Month Momentum % | -26.77 | |||||
12-1 Month Momentum % | 24.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.87 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -6.8 | |||||
Shareholder Yield % | -0.38 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -1736.62 | |||||
Net Margin % | -1788.21 | |||||
EBITDA Margin % | -1731.81 | |||||
FCF Margin % | -1870.64 | |||||
OCF Margin % | -1846.72 | |||||
ROE % | -110.71 | |||||
ROA % | -39.19 | |||||
ROIC % | -45.83 | |||||
3-Year ROIIC % | -9.01 | |||||
ROC (Joel Greenblatt) % | -959.72 | |||||
ROCE % | -89.15 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 54.57 | |||||
PB Ratio | 6.37 | |||||
EV-to-EBIT | -2.04 | |||||
EV-to-Forward-EBIT | -1.78 | |||||
EV-to-EBITDA | -2.1 | |||||
EV-to-Revenue | 36.35 | |||||
EV-to-Forward-Revenue | 34.91 | |||||
EV-to-FCF | -1.97 | |||||
Price-to-GF-Value | 3.42 | |||||
Earnings Yield (Greenblatt) % | -49.02 | |||||
FCF Yield % | -33.39 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AC Immune SA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 3.988 | ||
| EPS (TTM) (€) | -0.71 | ||
| Beta | 0.8795 | ||
| 3-Year Sharpe Ratio | 0.37 | ||
| 3-Year Sortino Ratio | 0.77 | ||
| Volatility % | 56.24 | ||
| 14-Day RSI | 51.39 | ||
| 14-Day ATR (€) | 0.157657 | ||
| 20-Day SMA (€) | 2.0589 | ||
| 12-1 Month Momentum % | 24.55 | ||
| 52-Week Range (€) | 1.638 - 3.365 | ||
| Shares Outstanding (Mil) | 101.77 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AC Immune SA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AC Immune SA Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-04 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 33 days | ||
| General meeting for 2026 | 2026-06-11 14:30 | 1.82 (-4.92%) | ||
| First quarter earnings results for 2026 | 2026-04-30 | 2.52 (-0.79%) | ||
| Annual report for 2025 | 2026-03-13 | 2.57 (-3.02%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-13 | 2.57 (-3.02%) | ||
| Guidance call for 2025 | 2025-12-11 09:00 | 2.16 (-2.93%) | ||
| Jefferies Global Healthcare Conference in London | 2025-11-18 04:30 | 2.78 (+0.00%) | ||
| Third quarter earnings results for 2025 | 2025-11-04 | 2.71 (-5.58%) | ||
| Second quarter earnings results for 2025 | 2025-08-05 | 1.85 (+3.11%) |
Show
Entries
AC Immune SA Frequently Asked Questions
What is AC Immune SA(STU:IMR)'s stock price today?
The current price of STU:IMR is €2.19. The 52 week high of STU:IMR is €3.37 and 52 week low is €1.64.
When is next earnings date of AC Immune SA(STU:IMR)?
The next earnings date of AC Immune SA(STU:IMR) is 2026-08-05 Est..
Does AC Immune SA(STU:IMR) pay dividends? If so, how much?
AC Immune SA(STU:IMR) does not pay dividend.
Press Release
Articles on AC Immune SA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers